試す - 無料

OZ BUDGET BOLSTERS HEALTHCARE

BioSpectrum Asia

|

May 2022

Circumstances have continued to evolve as the COVID-19 Omicron variant has added further pressure to Australia's healthcare sector, as well as increasing supply chain disruptions, bringing about staff shortages and reducing household spending.

- Narayan Kulkarni

OZ BUDGET BOLSTERS HEALTHCARE

With a Federal election due on May 21, 2022 to elect members of the 47th Parliament of Australia, Josh Frydenberg, Treasurer of the Commonwealth of DL 0650ERERE INITIE Australia presented the Federal Budget on March 29. The Coalition Government led by Scott Morrison is investing in a stronger health system as part of its plan for a stronger future through a record $132 billion in 2022-23 Budget, increasing to $140 billion in 2025-26, with a total commitment of $537 billion over the next four years. This record funding will ensure Australians have access to improved healthcare, when and where they need it, helping them to lead healthier lives, with improved health outcomes and to provide ongoing protection against COVID-19.

"The Federal government is committed to its Long Term National Health Plan, through important and strategic investments to deliver the world's best health care system to the Australians, including $537 billion over the next four years, up $34 billion compared to the 2021-22 Budget; $45.5 billion over four years to access more affordable medicines through the Pharmaceutical Benefits Scheme (PBS), and more than $2.4 billion this Budget to add vital new medicines to the PBS," said Greg Hunt, Minister for Health and Aged Care, Government of Australia.

BioSpectrum Asia からのその他のストーリー

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits

US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation

US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio

Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema

A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing

Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO

Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

IIT-D and AIIMS develop swallowable microdevice for microbiome study

Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Ambitious research to develop multivalent vaccines against multiple deadly filoviruses

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

time to read

1 min

BioSpectrum Asia Feb 2026

Translate

Share

-
+

Change font size